Detalles de la búsqueda
1.
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
Lancet Oncol
; 22(9): 1230-1239, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34310904
2.
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health.
Oncologist
; 26(10): e1786-e1799, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34196068
3.
FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer.
Oncologist
; 26(1): e164-e172, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33017510
4.
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate Cancer.
Oncologist
; 26(2): 139-146, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33145877
5.
A novel approach for personalized response model: deep learning with individual dropout feature ranking.
J Pharmacokinet Pharmacodyn
; 48(1): 165-179, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33104924
6.
An Analysis of Recent FDA Oncology Scientific Publications.
Oncologist
; 25(3): 266-270, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32162806
7.
Optimal unified combination rule in application of Dempster-Shafer theory to lung cancer radiotherapy dose response outcome analysis.
J Appl Clin Med Phys
; 17(1): 4-11, 2016 01 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-26894343
8.
Phase transitions in biogenic amorphous calcium carbonate.
Proc Natl Acad Sci U S A
; 109(16): 6088-93, 2012 Apr 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-22492931
9.
Trends in the approval of cancer therapies by the FDA in the twenty-first century.
Nat Rev Drug Discov
; 22(8): 625-640, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37344568
10.
Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses.
J Clin Oncol
; 40(8): 847-854, 2022 03 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34890212
11.
FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC.
Clin Cancer Res
; 28(11): 2221-2228, 2022 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35101885
12.
Model Development of CDK4/6 Predicted Efficacy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.
JCO Clin Cancer Inform
; 5: 758-767, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34297598
13.
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma.
Clin Cancer Res
; 27(4): 922-927, 2021 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32962979
14.
FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer.
Clin Cancer Res
; 27(8): 2126-2129, 2021 04 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33188141
15.
The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology.
Clin Cancer Res
; 27(19): 5161-5167, 2021 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33910935
16.
FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast Cancer.
Clin Cancer Res
; 27(5): 1220-1226, 2021 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33055172
17.
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.
Clin Cancer Res
; 27(7): 1842-1849, 2021 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33168657
18.
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice.
Eur J Cancer
; 157: 140-152, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34508996
19.
Tuning the Wettability of Metal-Organic Frameworks via Defect Engineering for Efficient Oil/Water Separation.
ACS Appl Mater Interfaces
; 12(30): 34413-34422, 2020 Jul 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-32551472
20.
Reducing Uninformative IND Safety Reports: A List of Serious Adverse Events anticipated to Occur in Patients with Lung Cancer.
Ther Innov Regul Sci
; 54(5): 1208-1214, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32865803